Entrada Therapeutics Inc (TRDA) Key Ratios

$7.12

up-down-arrow $-0.05 (-0.70%)

As on 04-Sep-2026 13:36EDT

Market cap

info icon

$273 Mln

Revenue (TTM)

info icon

$5 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

1.2

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 2.63 -53.95 -94.10 -52.39 --
EBIT -7.68 0.46 -114.50 -181.38 -223.42
Net Profit -7.67 0.79 -126.00 -123.30 -223.59
EPS -6.69 2.86 -122.70 -22.92 -183.12
Book Value -- -- -25.69 2.96 --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -173.65-226.49-3,520.25-561.8431.54
Net Margin info --161,522.58-3,537.73----
Return on equity info -7.50-19.13-61.45-39.1319.56
Return on Capital info -6.67-18.30---34.0316.44
Return on Assets info -6.83-16.10-42.03-31.8113.18
Debt to Equity (x) info ----0.000.170.14
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
--
-34.03
16.44
-2.43
-32.56
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-61.45

Lower than Peers by 21.05

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
-61.45
-39.13
19.56
-2.94
-34.21
Peer Median
-40.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-42.03

Lower than Peers by 11.05

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
-42.03
-31.81
13.18
-1.85
-31.35
Peer Median
-30.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-3,520.25

Lower than Peers by 3,436.63

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
-3,520.25
-561.84
31.54
9.34
-384.99
Peer Median
-83.62
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-3,537.73

Lower than Peers by 3,445.06

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
-3,537.73
-565.48
31.13
-5.18
-346.23
Peer Median
-92.67
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

Lower than Peers by 0.00

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
0.00
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

-94.10

Lower than Peers by 148.06

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
-94.10
-0.88
0.63
4.11
--
Peer Median
53.95
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-114.50

Lower than Peers by 113.70

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
-114.50
-314.82
451.47
112.40
-90.21
Peer Median
-0.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-126.00

Lower than Peers by 118.70

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
-126.00
-319.04
1,081.69
92.36
-74.66
Peer Median
-7.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-122.70

Lower than Peers by 137.35

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
-122.70
-3.28
8.61
0.93
-0.16
Peer Median
14.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-39.78

Lower than Peers by 29.60

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
-39.78
--
--
--
--
Peer Median
-10.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
--
0.17
0.14
0.28
0.12
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.02

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
0.02
0.01
0.02
0.03
0.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

10.89

Higher than Peers by 5.08

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
10.89
12.53
11.15
2.33
9.55
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

10.89

Higher than Peers by 5.19

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
10.89
--
--
2.33
--
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
--
--
--
--
-36.95
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

17.41

Lower than Peers by 1.73

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
17.41
10.14
1.75
4.56
--
Peer Median
19.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.01

Lower than Peers by 0.05

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
0.01
0.06
0.42
0.36
0.09
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
--
44.95
8.28
16.64
12.61
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
--
--
0.00
0.00
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
--
291.95
364.77
16.94
645.31
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
--
--
-356.48
-0.30
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
--
-2.96
11.34
-75.32
-4.85
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

1.17

Lower than Peers by 4.01

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
1.17
1.39
1.74
2.08
1.99
Peer Median
5.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

1.58

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
1.58
-1.27
5.46
14.75
-2.74
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

273

Higher than Peers by 127

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Entrada Therapeutics Inc (TRDA)
273
--
--
--
--
Peer Median
146
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...